Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPECTRA trial of half-dose photodynamic therapy versus eplerenone for chronic central serous chorioretinopathy
NL-OMON50407Phase 4Active, not recruiting
- Sponsor
- Leiden University Medical Center
- Start
- Feb 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of verteporfin and eplerenone in Central Serous Chorioretinopathy (CSCR) (2 arms), sponsored by Leiden University Medical Center. Primary endpoint: Complete resolution of subretinal fluid on OCT at 3 months. Started Feb 2017; status: active, not recruiting.
02
Drugs
verteporfineplerenone
03
Conditions
Central Serous Chorioretinopathy (CSCR)
Beyond the preview
Go deeper on NL-OMON50407.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON50407.